These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 15534491)

  • 21. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.
    Jäger E; Jäger D; Karbach J; Chen YT; Ritter G; Nagata Y; Gnjatic S; Stockert E; Arand M; Old LJ; Knuth A
    J Exp Med; 2000 Feb; 191(4):625-30. PubMed ID: 10684854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1.
    Campos-Perez J; Rice J; Escors D; Collins M; Paterson A; Savelyeva N; Stevenson FK
    Int J Cancer; 2013 Sep; 133(6):1400-7. PubMed ID: 23494538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.
    Bender A; Karbach J; Neumann A; Jäger D; Al-Batran SE; Atmaca A; Weidmann E; Biskamp M; Gnjatic S; Pan L; Hoffman E; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2007 Oct; 7():16. PubMed ID: 17944437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer.
    Sonpavde G; Wang M; Peterson LE; Wang HY; Joe T; Mims MP; Kadmon D; Ittmann MM; Wheeler TM; Gee AP; Wang RF; Hayes TG
    Invest New Drugs; 2014 Apr; 32(2):235-242. PubMed ID: 23609828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
    Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
    Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
    J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
    Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
    Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
    Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
    Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
    Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
    Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.
    Gnjatic S; Atanackovic D; Jäger E; Matsuo M; Selvakumar A; Altorki NK; Maki RG; Dupont B; Ritter G; Chen YT; Knuth A; Old LJ
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8862-7. PubMed ID: 12853579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population.
    Ohkuri T; Sato M; Abe H; Tsuji K; Yamagishi Y; Ikeda H; Matsubara N; Kitamura H; Nishimura T
    Cancer Sci; 2007 Jul; 98(7):1092-8. PubMed ID: 17488334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
    Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
    Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
    Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
    Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
    Chen JL; Dunbar PR; Gileadi U; Jäger E; Gnjatic S; Nagata Y; Stockert E; Panicali DL; Chen YT; Knuth A; Old LJ; Cerundolo V
    J Immunol; 2000 Jul; 165(2):948-55. PubMed ID: 10878370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
    Fourcade J; Kudela P; Andrade Filho PA; Janjic B; Land SR; Sander C; Krieg A; Donnenberg A; Shen H; Kirkwood JM; Zarour HM
    J Immunother; 2008 Oct; 31(8):781-91. PubMed ID: 18779741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
    Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM
    Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
    Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
    Karbach J; Pauligk C; Bender A; Gnjatic S; Franzmann K; Wahle C; Jäger D; Knuth A; Old LJ; Jäger E
    Int J Cancer; 2006 Feb; 118(3):668-74. PubMed ID: 16152624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.